Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
The new hospital is expected to open by March'24
Submissions for Ruminant Well-Being Awards and Gustav Rosenberger Memorial Fund grant open now
Empowers the lab to do more in less time within the existing floor plan by integrating clinical chemistry and immunoassay testing onto a single platform
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
Fortis Memorial Research Institute is the only hospital in India and South Asia to acquire the machine
A team of experts at Fortis Gurugram conducted 3-dimensional mapping with the help of the new system Carto version 7 to precisely map the source of the arrhythmia. It was detected that the arrhythmia was coming from the conduction system i.e. body’s natural wiring.
Agilent Technologies Inc. announced the contribution of Agilent AriaMx Real-Time qPCR instruments to five research hospitals in India to support their COVID-19 initiatives and help them serve the community at large
Subscribe To Our Newsletter & Stay Updated
